ReviewExperimental biology and medicine (Maywood, N.J.)2024
Bridging the gap: a translational perspective in spinal cord injury.
Review in Experimental biology and medicine (Maywood, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Tissue engineering for traumatic spinal cord injury: Research advances and clinical translation.Bioactive materials · 2026Review
- ID3 -depleted human induced pluripotent stem cell-derived neural stem/progenitor cells promote neurorepair.Neural regeneration research · 2026Article
- An inflammation-targeted lipid nanoparticle inhibiting ferroptosis for spinal cord injury repair.Materials today. Bio · 2026Article
- Cryopreserved Mucosal Olfactory Ensheathing Cells Promote Functional Recovery After Dorsal Root Injury.Cells · 2026Article
- Mesenchymal Stromal/Stem Cells in Chronic Incomplete Traumatic Spinal Cord Injury: A Phase I/II Double-Blind Placebo-Controlled Multicentre Trial.Biomedicines · 2026Article
- Fetal rat neural progenitor cell transplantation after spinal cord injury improves motor recovery following optogenetic stimulation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Developing an NT3-loaded exosomal biodegradable conductive hydrogel combined with EA for targeted treatment of spinal cord injury.Materials today. Bio · 2025Article
- Advances and New Therapies in Traumatic Spinal Cord Injury.Journal of clinical medicine · 2025Review
- Experimental Biology and medicine conference thematic issue introduction.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Injury to Time of Marked Recovery as a New Acute Spinal Cord Injury Outcome Measurement for Statistical Analysis of Interventions and Drug Treatments.Neurotrauma reportsArticle
- Correlation between MRI high-signal parameters and prognosis in cervical spinal cord injury without fracture and dislocation.Frontiers in neurologyArticle
- Acquisition-Related Heterogeneity in Human Spinal Cord Donors: A 10-Year Organ Donation-Integrated Procurement Cohort for Translational Spinal Cord Injury Research.Neurotrauma reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic spinal cord injury (SCI) is a devastating and complex condition to treat with no curative options. In the past few decades, rapid advancements in our understanding of SCI pathophysiology as well as the mergence of new treatments has created more optimism. Focusing on clinical translation, this paper provides a comprehensive overview of SCI through its epidemiology, pathophysiology, currently employed management strategies, and emerging therapeutic approaches. Additionally, it emphasizes the importance of addressing the heavy quality of life (QoL) challenges faced by SCI patients and their desires, providing a basis to tailor patient-centric forms of care. Furthermore, this paper discusses the frequently encountered barriers in translation from preclinical models to clinical settings. It also seeks to summarize significant completed and ongoing SCI clinical trials focused on neuroprotective and neuroregenerative strategies. While developing a cohesive regenerative treatment strategy remains challenging, even modest improvements in sensory and motor function can offer meaningful benefits and motivation for patients coping with this highly debilitating condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.